Insmed reported $-88566000 in EBIT for its second fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Ebit Change
Acelrx Pharmaceuticals ACRX:US $ -9684000 20K
Alexion Pharmaceuticals ALXN:US $ 816.7M 185.9M
Arena Pharmaceuticals ARNA:US $ -144391000 12.4M
Biomarin Pharmaceutical BMRN:US $ 13.86M 13.56M
Cytokinetics CYTK:US $ -54797000 14.19M
Dynavax Technologies DVAX:US $ 9.68M 19.34M
Flexion Therapeutics FLXN:US $ -16882000 6.26M
Gilead Sciences GILD:US $ 2262M 639M
Heron Therapeutics HRTX:US $ -60469000 8.36M
Insmed INSM:US $ -88566000 4.73M
Mirati Therapeutics MRTX:US $ -164186000 31.76M
Novartis NVS:US 3.4B 415M
Regeneron Pharmaceuticals REGN:US $ 3347.2M 2234.5M
Sarepta Therapeutics SRPT:US $ -167574000 25.71M
Seattle Genetics SGEN:US $ -89603000 32.82M
Ultragenyx Pharmaceutical RARE:US $ -82776000 23.79M
Vertex Pharmaceuticals VRTX:US $ -36.36M 920.29M